Description: Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Home Page: www.gilead.com
333 Lakeside Drive
Foster City,
CA
94404
United States
Phone:
650 574 3000
Officers
| Name | Title |
|---|---|
| Mr. Daniel P. O'Day | Chairman & CEO |
| Mr. Andrew D. Dickinson | Chief Financial Officer |
| Ms. Deborah H. Telman J.D. | Executive VP of Corporate Affairs, General Counsel & Corporate Secretary |
| Ms. Johanna Mercier | Chief Commercial Officer |
| Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer |
| Ms. Sandra Patterson | Senior VP, Corporate Controller & Principal Accounting Officer |
| Ms. Jacquie Ross C.F.A. | Vice President of Investor Relations |
| Ms. Jyoti K. Mehra | Executive Vice President of Human Resources |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio |
| Dr. Rudolf Ertl | Senior Vice President of Commercial Operations of Australia, Canada, Europe |
Exchange: XETRA
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 12.3153 |
|---|---|
| Trailing PE: | 973.4444 |
| Price-to-Book MRQ: | 6.2561 |
| Price-to-Sales TTM: | 3.9125 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 18000 |